EGYPTIAN INTERNATIONAL PHARMACEUTICALS (EIPICO)
PHAR

EGX

Current Price
EGP
EGP (%)
Price Upon Recommendation
50.26 EGP
Target Price from Recommendation

59.65 EGP

+18.50%
Holding Period

From 3 to 6 months

Final Recommendation

Buy stock at the current price

Valid Until

July 18, 2025 at 11:59:59 PM

Risk Assessment

Medium

Confidence Score

78.00%

Potential Growth

18.50%

Investment Reason

PHAR demonstrates strong fundamentals and aligns with Egypt's healthcare sector growth, driven by increasing demand and regulatory support. Recent market resilience and favorable valuations enhance its appeal.

Overview
Recent Performance

PHAR has shown steady growth, with a 12% YTD increase amid EGX's broader bullish trends. It outperformed peers in the healthcare sector, supported by strong Q1 earnings.

Economic Factors

Egypt's economic reforms, rising healthcare spending, and currency stability underpin PHAR's growth potential amid regional market volatility.

Competitive Positioning

PHAR holds a leading position in Egypt's pharmaceutical market, with a diversified portfolio and strategic partnerships enhancing distribution networks.

Analysis Summary

PHAR is poised for growth due to sector tailwinds, strong financials, and strategic market positioning. Risks include regulatory changes and currency fluctuations, but upside potential outweighs concerns.

Key Points
  • Strong Q1 earnings and sector leadership position PHAR for growth.
  • 18.5% upside potential with a target price of 59.65 EGP.
  • Medium risk with Egypt's economic reforms mitigating volatility.
  • Strategic partnerships enhance distribution and market reach.
Recommendations